

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <b>GREIG RUSSELL</b> <hr/> (Last) (First) (Middle) <b>C/O BIOMX LTD.,</b> <b>22 EINSTEIN ST., 5TH FLOOR</b> <hr/> (Street) <b>NESS ZIONA, L3</b> <b>7414003</b> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>BiomX Inc. [ PHGE ]</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <b>07/28/2021</b>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I – Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/28/2021		P		3,750	A	\$4 <sup>(1)</sup>	3,750	I	See Footnote (3)

**Table II – Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Common Stock Warrant	\$5	07/28/2021		P		2,813		01/28/2022 <sup>(2)</sup>	01/28/2027	Common Stock	2,813	<sup>(1)</sup>	2,813	I	See Footnote (3)

**Explanation of Responses:**

- The common stock and common stock warrant were acquired in the issuer's registered direct offering of units, in which each unit consisted of one share of common stock and one common stock warrant to purchase 0.75 of a share of common stock, at a price of \$4.00 per unit. The price paid per unit is reflected in Table I.
- The common stock warrant will be exercisable six months after the date of issuance, at an exercise price of \$5.00 per share and will expire five years from the date such warrant first becomes exercisable.
- The common stock and common stock warrant are held by Greig Biotechnology Global Consulting Inc.; Mr. Greig, as the sole director, an officer and the controlling shareholder of Greig Biotechnology Global Consulting Inc., may be deemed to be a beneficial owner of these shares, but Mr. Greig disclaims such beneficial ownership except to the extent of his pecuniary interest therein.

**Remarks:**

/s/ Russell Greig  
\*\* Signature of Reporting Person

07/30/2021  
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.